Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Authors’ Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?

Canagliflozin and iron metabolism in the CREDENCE trial

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

Compositions and methods for treating and preventing kidney disease

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy”

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Pers/media

Hoe afslankmedicijnen het hele lichaam veranderen: ‘Mijn hoofd roept niet meer om eten’

智康弘义宣布SC0062临床II期糖尿病肾病队列研究达到12周主要终点 | 项目进展

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Semaglutide in patinenten met nierziekte

BioCity announces its endothelin receptor A selective antagonist SC0062 met the ...

Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

New Hope for Treating Chronic Kidney Disease in Type 1 Diabetes